All data are based on the daily closing price as of October 9, 2024
d

Daewon Pharmaceutical

003220.KO
10.85 USD
0.06
+0.56%

Overview

Last close
10.85 usd
Market cap
229.98M usd
52 week high
13.87 usd
52 week low
10.06 usd
Target price
16.12 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
0.5474
Price/Book Value
1.1569
Enterprise Value
325.66M usd
EV/Revenue
0.7733
EV/EBITDA
10.2517

Key financials

Revenue TTM
421.15M usd
Gross Profit TTM
129.86M usd
EBITDA TTM
33.30M usd
Earnings per Share
N/A usd
Dividend
0.22 usd
Total assets
582.84B usd
Net debt
N/A usd

About

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
  • Symbol
    003220.KO
  • Exchange
    KO
  • Isin
    KR7003220001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.daewonpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top